{"organizations": [], "uuid": "0aa8a47f3d123fb4b2e2daee2520e7ae00bfa338", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180119.html", "section_title": "Archive News &amp; Video for Friday, 19 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shenzhen-hepalink-pharmaceutical-u/brief-shenzhen-hepalink-pharmaceutical-unit-gets-approval-for-new-drug-clinical-trial-in-australia-idUSL3N1PE21Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Shenzhen Hepalink Pharmaceutical unit gets approval for new drug clinical trial in Australia", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-19T13:12:00.000+02:00", "replies_count": 0, "uuid": "0aa8a47f3d123fb4b2e2daee2520e7ae00bfa338"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shenzhen-hepalink-pharmaceutical-u/brief-shenzhen-hepalink-pharmaceutical-unit-gets-approval-for-new-drug-clinical-trial-in-australia-idUSL3N1PE21Q", "ord_in_thread": 0, "title": "BRIEF-Shenzhen Hepalink Pharmaceutical unit gets approval for new drug clinical trial in Australia", "locations": [], "entities": {"persons": [], "locations": [{"name": "australia", "sentiment": "none"}], "organizations": [{"name": "brief-shenzhen hepalink pharmaceutical", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "shenzhen hepalink pharmaceutical co ltd", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 19 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd :\n* Says its controlling Shenzhen-based biotech subsidiary gets approval for new drug Ib/IIa clinical trial in Australia\n* The new drug is used for treatment of hyperlipemia\nSource text in Chinese: goo.gl/4PZG6r\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/4PZG6r", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-19T13:12:00.000+02:00", "crawled": "2018-01-20T17:29:47.007+02:00", "highlightTitle": ""}